CA2251704A1 - Administration topique d'agents antimicrobiens dans le traitement de maladies bacteriennes systemiques - Google Patents
Administration topique d'agents antimicrobiens dans le traitement de maladies bacteriennes systemiques Download PDFInfo
- Publication number
- CA2251704A1 CA2251704A1 CA002251704A CA2251704A CA2251704A1 CA 2251704 A1 CA2251704 A1 CA 2251704A1 CA 002251704 A CA002251704 A CA 002251704A CA 2251704 A CA2251704 A CA 2251704A CA 2251704 A1 CA2251704 A1 CA 2251704A1
- Authority
- CA
- Canada
- Prior art keywords
- antimicrobial agent
- premafloxacin
- dmso
- topical
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000004599 antimicrobial Substances 0.000 title claims abstract description 36
- 230000009885 systemic effect Effects 0.000 title claims abstract description 23
- 208000035143 Bacterial infection Diseases 0.000 title claims abstract description 10
- 238000011200 topical administration Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 12
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 claims abstract description 8
- 229950009592 cefquinome Drugs 0.000 claims abstract description 8
- 229960003276 erythromycin Drugs 0.000 claims abstract description 6
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 claims abstract description 4
- 229960005090 cefpodoxime Drugs 0.000 claims abstract description 4
- 229950002166 premafloxacin Drugs 0.000 claims abstract 14
- 241000124008 Mammalia Species 0.000 claims abstract 7
- SUQUWONDIBHQOZ-NWDGAFQWSA-N premafloxacin Chemical compound C1[C@H]([C@H](C)NC)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1OC SUQUWONDIBHQOZ-NWDGAFQWSA-N 0.000 claims abstract 7
- -1 premafloxacin ester Chemical class 0.000 claims abstract 7
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract 6
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims abstract 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims abstract 3
- 229930182566 Gentamicin Natural products 0.000 claims abstract 3
- 229960003405 ciprofloxacin Drugs 0.000 claims abstract 3
- 229960000740 enrofloxacin Drugs 0.000 claims abstract 3
- 229960002518 gentamicin Drugs 0.000 claims abstract 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 126
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000037396 body weight Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 8
- 230000000699 topical effect Effects 0.000 description 43
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 39
- 239000003795 chemical substances by application Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 15
- 230000000845 anti-microbial effect Effects 0.000 description 13
- 230000001580 bacterial effect Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 5
- 229940055577 oleyl alcohol Drugs 0.000 description 5
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000187722 Micromonospora echinospora Species 0.000 description 4
- YBHQCJILTOVLHD-YVMONPNESA-N Mirin Chemical compound S1C(N)=NC(=O)\C1=C\C1=CC=C(O)C=C1 YBHQCJILTOVLHD-YVMONPNESA-N 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 3
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229960005229 ceftiofur Drugs 0.000 description 3
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229960002418 ivermectin Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 241001293418 Mannheimia haemolytica Species 0.000 description 2
- 241001674048 Phthiraptera Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 101001126084 Homo sapiens Piwi-like protein 2 Proteins 0.000 description 1
- 206010069803 Injury associated with device Diseases 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100029365 Piwi-like protein 2 Human genes 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000004540 pour-on Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- NMGNJWORLGLLHQ-UHFFFAOYSA-M sulcofuron-sodium Chemical compound [Na+].[O-]S(=O)(=O)C1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 NMGNJWORLGLLHQ-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 1
- 229960000223 tilmicosin Drugs 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4160496P | 1996-05-10 | 1996-05-10 | |
| US60/041,604 | 1996-05-10 | ||
| PCT/US1997/007124 WO1997042954A1 (fr) | 1996-05-10 | 1997-05-05 | Administration topique d'agents antimicrobiens dans le traitement de maladies bacteriennes systemiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2251704A1 true CA2251704A1 (fr) | 1997-11-20 |
Family
ID=29547785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002251704A Abandoned CA2251704A1 (fr) | 1996-05-10 | 1997-05-05 | Administration topique d'agents antimicrobiens dans le traitement de maladies bacteriennes systemiques |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2251704A1 (fr) |
-
1997
- 1997-05-05 CA CA002251704A patent/CA2251704A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6191143B1 (en) | Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases | |
| JP4342440B2 (ja) | 駆虫性動物用均質経口ペースト | |
| ES2228932T3 (es) | Procedimiento de tratamiento del carcinoma positivo de estrogenos. | |
| EP1713466B1 (fr) | Composition antiparasitaire contenant un sel organique amine de closantel | |
| US20020086867A1 (en) | Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria | |
| AU721819B2 (en) | Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases | |
| JP2003522108A (ja) | マクロライドの水溶液 | |
| JPH0623100B2 (ja) | 改良された抗寄生虫活性を持つ非水性イベルメクチン処方剤 | |
| NZ501160A (en) | Subcutaneously injectable quinolone formulations with zinc or magnesium compounds and a co-solvent | |
| EP0274714B1 (fr) | Préparation topique contenant de l'ofloxacine | |
| EP0925065B1 (fr) | Composees d'erythromycine miscibles dans l'eau | |
| EP2561876B1 (fr) | Formulations d'acide désoxycholique et sels associés | |
| RU2270836C2 (ru) | 9a-n-[n`-(фенилсульфонил)карбамоил)производные 9-дезоксо-9-дигидро-9a-аза-9a-гомоэритромицина a и 5-o-дезозаминил-9-дезоксо-9-дигидро-9a-аза-9a-гомоэритронолида a, способ их получения и фармацевтическая композиция на их основе | |
| EP1251874B1 (fr) | Compositions pharmaceutiques stabilisees comprenant un antibiotique et un expectorant, et leur procede de preparation | |
| CA2251704A1 (fr) | Administration topique d'agents antimicrobiens dans le traitement de maladies bacteriennes systemiques | |
| AU730172B2 (en) | 8a-azalides as veterinary antimicrobial agents | |
| EP0238207B1 (fr) | Mélanges bactéricides | |
| WO2022025831A1 (fr) | Compositions pharmaceutiques pour injection comprenant de la tulathromycine | |
| WO2023204380A1 (fr) | Support de substance physiologiquement active | |
| CA2079328C (fr) | Formulation veterinaire d'amoxycilline et d'acide clavunalique et leurs derives | |
| JP2565396B2 (ja) | 放射線又は薬物による副作用軽減剤 | |
| JPS63264418A (ja) | 安定化された眼科用組成物 | |
| US6979676B2 (en) | Pharmaceutical composition containing and indolopyrrolocarbazole derivative | |
| EA005308B1 (ru) | Препараты эстрамустинфосфата для парентерального применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |